Major Milestone: Peer-reviewed study confirms GastroPanel® can reduce endoscopy waiting lists by 87%
We are proud to share a breakthrough publication in the prestigious journal Helicobacter (2026). This peer-reviewed study validates GastroPanel® as a powerful clinical triage tool for gastric cancer risk stratification.
As healthcare systems worldwide face increasing pressure, this evidence proves that non-invasive testing is no longer just an alternative—it is a necessity for efficient patient care.
Key Findings from the Study:
- Validated triage tool: Confirms GastroPanel® as a reliable clinical triage tool for accurate gastric cancer risk stratification.
- 87% reduction: Real-world implementation in Molina, Chile, saw endoscopy waiting lists slashed by 87%.
- Smart prioritization: Enables the safe prioritization of high- and intermediate-risk patients while reducing unnecessary procedures.
- Global scalability: Offers a practical, evidence-based solution to the global challenge of healthcare resource scarcity.
“This is a highly significant milestone,” says Jussi Hahtela, CEO of Biohit Oyj. “We now have peer-reviewed evidence showing that endoscopy waiting lists can be reduced by up to 87% without compromising patient safety… GastroPanel® offers a practical solution to allocate resources more effectively while improving early detection.”